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Melatonin modulates the fetal cardiovascular defense response to
acute hypoxia
Abstract: Experimental studies in animal models supporting protective eﬀects
on the fetus of melatonin in adverse pregnancy have prompted clinical trials in
human pregnancy complicated by fetal growth restriction. However, the eﬀects
of melatonin on the fetal defense to acute hypoxia, such as that which may
occur during labor, remain unknown. This translational study tested the
hypothesis, in vivo, that melatonin modulates the fetal cardiometabolic
defense responses to acute hypoxia in chronically instrumented late gestation
fetal sheep via alterations in fetal nitric oxide (NO) bioavailability. Under
anesthesia, 6 fetal sheep at 0.85 gestation were instrumented with vascular
catheters and a Transonic ﬂow probe around a femoral artery. Five days later,
fetuses were exposed to acute hypoxia with or without melatonin treatment.
Fetal blood was taken to determine blood gas and metabolic status and
plasma catecholamine concentrations. Hypoxia during melatonin treatment
was repeated during in vivo NO blockade with the NO clamp. This technique
permits blockade of de novo synthesis of NO while compensating for the tonic
production of the gas, thereby maintaining basal cardiovascular function.
Melatonin suppressed the redistribution of blood ﬂow away from peripheral
circulations and the glycemic and plasma catecholamine responses to acute
hypoxia. These are important components of the fetal brain sparing response
to acute hypoxia. The eﬀects of melatonin involved NO-dependent
mechanisms as the responses were reverted by fetal treatment with the NO
clamp. Melatonin modulates the in vivo fetal cardiometabolic responses to
acute hypoxia by increasing NO bioavailability.
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Introduction
Melatonin is mostly associated with circadian and sea-
sonal rhythmicity, but it is also important in reproduction
[1]. Maternal plasma melatonin levels are elevated during
pregnancy, reaching a maximum at term and then return-
ing to basal levels soon after delivery [2]. The expression
of melatonin receptors in the placenta and fetal tissues fur-
ther suggests a functional role in feto-placental develop-
ment [3]. Melatonin is also a powerful antioxidant [4], and
the potency of its antioxidant actions relates directly to its
combined ability to scavenge free radicals [5], to enhance
the expression and/or activity of antioxidant enzymes [6],
and to reduce the leakage of electrons from the mitochon-
drial electron transport chain [7, 8]. We and others have
shown that the antioxidant actions of melatonin increase
umbilical blood ﬂow and it is protective on the placenta
and on fetal cardiovascular function in pregnancy compli-
cated by chronic adverse intrauterine conditions [9–11]. In
addition, melatonin has been shown to protect the villous
trophoblast against hypoxia-reperfusion-induced oxidative
stress and apoptosis [12]. These ﬁndings have led to a
phase I clinical trial to test the therapeutic eﬃcacy of
maternal oral melatonin administration in women with a
pregnancy complicated by fetal growth restriction [13].
However, the eﬀects of melatonin on the capacity of the
fetus to respond to episodes of acute hypoxic stress, such
as that which occurs during labor and delivery, remain
completely unknown.
The fetal defense to acute episodes of hypoxic stress is
contingent on integrated cardiovascular and metabolic
responses to facilitate fetal survival during the period of
reduced oxygen availability. The fetal metabolic responses
involve an increase in glucose and lactate in the fetal circu-
lation [14]. The cardiovascular defense to acute hypoxia
includes bradycardia and peripheral vasoconstriction [15,
16]. The latter aids the redistribution of the fetal cardiac
output, and thereby of oxygen and glucose delivery, away
from peripheral and toward essential vascular beds, such
as the cerebral circulation; this response is also known as
the “fetal brain sparing eﬀect” [16]. The physiology of the
fetal cardiovascular responses to acute hypoxia is well
established. Fetal bradycardia and the peripheral vasocon-
striction are triggered exclusively by a carotid chemoreﬂex
[17]. The peripheral vasoconstriction is then maintained by
the release of constrictor agents into the fetal circulation,
including catecholamines [18, 19]. Recently, we have also
made the discovery that a vascular oxidant tone, deter-
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mined by the balance between the superoxide anion and
nitric oxide (O2 : NO), is operational in the late gestation
fetus [20]. This oxidant tone acts locally at the level of the
fetal vasculature, whereby an increase in the ratio promotes
constriction and a decrease favors vasodilatation [9, 21, 22].
Consequently, fetal treatment with agents that increase NO
bioavailability opposes chemoreﬂex and humoral constric-
tor inﬂuences and thereby blunts the fetal peripheral vaso-
constrictor response to acute hypoxia [20, 23].
This study tested the hypothesis that melatonin modu-
lates the fetal defense response to acute episodes of
hypoxia by aﬀecting NO bioavailability. The hypothesis
was tested by investigating the in vivo actions of exoge-
nous melatonin on fetal cardiovascular and metabolic
function during acute hypoxic stress using the late gesta-
tion ovine fetus as an experimental model. Diﬀerent doses
of melatonin were used to address any dose-dependent
actions. Acute hypoxia was induced with and without
in vivo NO blockade using an established NO clamp
[24–26], to determine which eﬀects of melatonin involved
NO-dependent mechanisms. Plasma concentrations of epi-
nephrine and norepinephrine were also measured to estab-
lish whether any eﬀects of melatonin on cardiometabolic
function involved alterations in circulating catecholamine
levels. Melatonin was infused directly into the fetal circula-
tion to isolate its direct eﬀects on the fetus independent of
confounding eﬀects on the maternal and/or the placental
physiology.
Methods
Surgical preparation
All procedures were approved by the Ethical Review Com-
mittee of the University of Cambridge. All procedures
were performed under the UK Animals (Scientiﬁc Proce-
dures) Act 1986 and conform to the Guide for the Care
and Use of Laboratory Animals published by the US
National Institutes of Health (NIH Publication No. 85-23,
revised 1996).
Six Welsh Mountain sheep fetuses were surgically in-
strumented for long-term recording at 124  1 days of
gestation (term is ca. 145 days) as previously described in
detail [27]. Under general anesthesia (1.5–2.0% halothane
in 50:50 O2:N2O), midline abdominal and uterine incisions
were made, the fetal hind limbs were exteriorized, and, on
one side, femoral arterial (i.d., 0.86 mm; o.d., 1.52 mm;
Critchley Electrical Products, Kingsgrove, NSW, Austra-
lia) and venous (i.d., 0.56 mm; o.d., 0.96 mm) catheters
were inserted. Another catheter was anchored onto the
fetal hind limb for recording of the reference amniotic
pressure. A Transonic ﬂow transducer was then positioned
around the contra-lateral femoral artery (2R or 3S). The
uterine incisions were closed in layers, the dead space of
the catheters was ﬁlled with heparinized saline (80 i.u. hep-
arin/mL in 0.9% NaCl), and the catheter ends were
plugged with sterile brass pins.
Postoperative care
During recovery, ewes had free access to hay and water and
were fed concentrates twice daily (100 g sheep nuts no. 6; H
& C Beart Ltd., Kings Lynn, UK). Antibiotics were admin-
istered daily to the ewe (0.20–0.25 mg/kg I.M. Depocillin;
Mycofarm, Cambridge, UK) and fetus I.V. and into the
amniotic cavity (150 mg/kg Penbritin; SmithKline Bee-
cham Animal Health, Welwyn Garden City, Hertfordshire,
UK). Following 72 hr of postoperative recovery, ewes were
transferred to metabolic crates where they were housed for
the remainder of the protocol. The fetal arterial and amni-
otic catheters were connected to sterile pressure transducers
(COBE; Argon Division, Maxim Medical, Athens, TX,
USA), and calibrated mean fetal arterial blood pressure
(corrected for amniotic pressure) and fetal heart rate (trig-
gered via a tachometer from the pulsitility in the arterial
blood pressure signal) were recorded continually using a
computerized Data Acquisition System (DAS; Department
of Physiology, Cambridge University, Cambridge, UK).
Experimental protocol
Following at least 5 days of postoperative recovery, all
fetuses were subjected to acute hypoxia experiments, car-
ried out on consecutive days in a randomized order
(Fig. 1). Each protocol consisted of a 3-hr period divided
into 1.5-hr normoxia, 0.5-hr hypoxia, and 1-hr recovery,
during a slow I.V. infusion of either heparinized saline vehi-
cle (0.5% ethanol-99.5% heparinized saline), treatment
R60
Saline vehicle infusion  
or  
Treatment with melatonin low or high
Normoxia [1.5 hr] Hypoxia [0.5 hr] Recovery [1 hr]
N0 N75 H30H15 R30
0 0.5 1.0 1.5 2.0 2.5Time (hr)
Time periods
3.0
H5
NO clamp
Fig. 1. Diagrammatic representation of the experimental protocol. The experimental protocol consisted of a 3-hr period divided into the
following: 1.5-hr normoxia, 0.5-hr hypoxia (black bar), and 1-hr recovery, during saline vehicle infusion (n = 6), treatment with melatonin
low (0.05  0.01 lg/kg/min; n = 6), treatment with melatonin high (0.5  0.1 lg/kg/min; n = 6), or treatment with melatonin high
during nitric oxide (NO) blockade with the NO clamp (n = 6; gray bar). Arrows represent times at which arterial blood samples were
collected.
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with a low dose of melatonin (0.05  0.01 lg/kg/min),
treatment with a high dose of melatonin (0.5  0.1 lg/kg/
min), or treatment with melatonin high during NO block-
ade with the NO clamp (Fig. 1). The doses of melatonin
were calculated retrospectively from the fetal weights
(3.4  0.3 kg) obtained at postmortem and were adminis-
tered to the fetus having been dissolved in 0.5% ethanol-
99.5% heparinized saline (80 i.u. heparin/mL in 0.9%
NaCl) solution. The doses were chosen to achieve the low-
est plasma concentrations compatible with melatonin hav-
ing the capacity to act as antioxidant [28, 29]. For
comparison, the high dose of melatonin used is ca. 32
times lower than that recommended for the prevention of
jet lag in humans [30]. The NO clamp is an established
technique previously validated in our laboratory that is
able to block the production of NO in vivo without aﬀect-
ing basal cardiovascular function [24–26]. In brief, a bolus
dose (100 mg/kg dissolved in 2 mL heparinized saline) of
L-NAME (NG-nitro-L-arginine methyl ester; Sigma Chem-
icals, Dorset, UK) was injected via the femoral artery,
immediately followed by fetal I.V. infusion with sodium ni-
troprusside (SNP; Sigma Chemicals; 5.1  2.0 lg/kg/min:
mean  1 S.D.; dissolved in heparinized saline). The infu-
sion rate of SNP was titrated to avoid any perturbation in
basal arterial blood pressure. While fetal treatment with
L-NAME alone leads to pronounced systemic vasocon-
striction and hypertension, combined treatment of the
fetus with both L-NAME and SNP compensates for the
tonic production of the gas, maintains basal cardiovascu-
lar function, and blocks de novo synthesis of NO during
stimulated conditions, such as during acute hypoxia. At
the end of the experimental protocol, the eﬀectiveness of
NO blockade by the NO clamp and the persistence of
L-NAME in the system were tested by withdrawal of the
SNP infusion. This unmasked the inﬂuence of fetal treat-
ment with L-NAME alone and led to a signiﬁcant increase
in arterial blood pressure, a fall in heart rate, and an increase
in femoral vascular resistance (FVR) (data not shown).
Acute hypoxic stress in the fetus was induced by mater-
nal inhalational hypoxia for 30 min by changing the con-
centrations of gases breathed by the ewe to 6% O2 in N2
with small amounts of CO2 (15 L/min air: 35 L/min N2:
1.5–2.5 L/min CO2) [25]. This mixture was designed to
reduce fetal PaO2 to ca. 10 mmHg while maintaining fetal
PaCO2. Following the 0.5-hr period of hypoxia, the ewe
was returned to breathing air for the 1-hr recovery period.
At the end of the experimental protocol, the ewes and
fetuses underwent euthanasia with a lethal dose of sodium
pentobarbitone (200 mg/kg I.V. Pentoject; Animal Ltd,
York, UK). The positions of the implanted catheters and
ﬂow probe were conﬁrmed, and the fetuses were weighed.
Blood sampling and hormone measurements
During the experimental protocol, descending aortic blood
samples were taken using sterile techniques from the fetus
at set time intervals to determine arterial blood gases and
pH (0.3 mL; Fig. 1). Arterial blood gas and pH measure-
ments were made using an ABL5 blood gas analyzer
(Radiometer; Copenhagen, Denmark; measurements
corrected to 39.5°C for the fetus). Values for percentage
saturation of hemoglobin with oxygen (Sat Hb) were
determined using a hemoximeter (OSM3; Radiometer). In
addition, blood glucose and lactate concentrations were
measured by an automated analyser (Yellow Springs 2300
Stat Plus Glucose/Lactate Analyser; YSI Ltd., Farnbor-
ough, UK). An additional 2 mL of arterial blood was col-
lected under sterile conditions for hormone analyses at set
intervals (Fig. 1, arrows). Samples were centrifuged and
the plasma obtained was then dispensed into prelabelled
tubes of either chilled heparin tubes (2 mL Li+/heparin
tubes; L. I. P. Ltd., Shipley, West Yorkshire, UK) con-
taining reduced glutathione (4 nmol per tube; G-4251;
Sigma Chemicals) and EGTA (5 nmol per tube; E-4378;
Sigma Chemicals) for catecholamine analysis or chilled
EDTA tubes (2 mL K+/EDTA; L.I.P., Ltd.) for the deter-
mination of circulating plasma concentrations of melato-
nin. All samples were stored at 80°C until analysis. All
hormone measurements were performed within 2 months
of sample collection.
Fetal plasma concentrations of melatonin were mea-
sured using RIA, as previously validated for use in ovine
plasma [9]. All samples were analyzed in duplicate at the
same time. Plasma samples were extracted with diethyl
ether prior to assaying. The assay used melatonin antise-
rum (batch no. 704 8483; Guildhay Antisera Ltd., Guild-
ford, Surrey, UK) and O-methyl-3H-labeled melatonin
(85 Ci mmol/L; Amersham Biosciences AB, SE-751 84,
Uppsala, Sweden) tracers. The sensitivity of the assay was
21.5 pmol/L, and the inter- and intra-assay coeﬃcients of
variation were both <15%. The melatonin antiserum
showed <1% cross-reactivity with N-acetyltryptamine,
6-hydroxy MT, N-acetyltryptophan, and other related
amines.
Fetal plasma epinephrine and norepinephrine concentra-
tions were measured by high-pressure liquid chromatogra-
phy (HPLC) using electrochemical detection as previously
described in detail [19, 31]. The samples were prepared by
the absorption of 250 lL of plasma onto acid-washed alu-
mina, and 20 lL aliquots of the 100 lL perchloric acid
elutes was injected onto the column. Dihydroxybenzyl-
amine was added as the internal standard to each plasma
sample before absorption. The limit of sensitivity for the
assay was 20 pg/mL for epinephrine and norepinephrine.
Recovery ranged from 63% to 97%, and all catecholamine
values were corrected for their respective recovery. The
interassay coeﬃcients of variation for epinephrine and
norepinephrine were 7.3% and 6.2%, respectively.
Data and statistical analyses
All variables are expressed as mean  S.E.M. Values for
arterial blood gases and pH are expressed at 0 (N0) and
75 (N75) min of normoxia, at 5 (H5), 15 (H15), and 30
(H30) min of hypoxia, and at 30 (R30) and 60 (R60) min
of recovery. Values for plasma concentrations of melato-
nin are expressed at 0 (N0) and 75 (N75) min of normoxia,
at 15 (H15) and 30 (H30) min of hypoxia, and at 60 (R60)
min of recovery. Summary measures analysis was applied
to the serial cardiovascular data to focus the number of
comparisons [32]. FVR was calculated using Ohm’s
principle by dividing fetal arterial blood pressure
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(corrected for amniotic pressure) by femoral blood ﬂow
(FBF). Area under the curve was calculated at 30-min
intervals (N1, N2, N3, H, R1, R2) for the absolute data
describing the fetal cardiovascular responses. Variables
were assessed statistically using a two-way ANOVA with
RM comparing the eﬀect of time, treatment, and interac-
tions between time and treatment. Where a signiﬁcant
eﬀect of time or treatment was indicated, the post hoc
Tukey test was used to isolate the statistical diﬀerences.
For all comparisons, statistical signiﬁcance was accepted
when P < 0.05.
Results
Basal values for plasma concentrations of melatonin in
the fetal circulation were below the detection limit of the
assay (0.1 nmol/L). During normoxia, treatment with
melatonin elevated fetal plasma concentrations of the
indole amine in a dose-dependent manner, with low doses
of melatonin treatment achieving concentrations of
2.5  0.4 nmol/L and high doses of melatonin treatment
achieving concentrations of 13.3  1.6 nmol/L (Fig. 2).
Neither acute hypoxia nor the application of the NO
clamp aﬀected signiﬁcantly the magnitude of the rise in
fetal plasma concentrations of melatonin during basal
conditions (Fig. 2). At the end of all treatments, fetal
plasma concentrations of melatonin returned toward pre-
infusion levels (Fig. 2).
Basal values for fetal arterial blood gas status were simi-
lar in all fetuses and were within the normal range for the
Welsh Mountain sheep fetus at ca. 130 days of gestation
(Table 1). Infusion with saline vehicle, treatment with
melatonin low, treatment with melatonin high, or treatment
with melatonin high during NO blockade had no eﬀect on
basal arterial blood gas status (Table 1). In all fetuses,
acute hypoxia induced signiﬁcant falls in PaO2, in Sat Hb,
and in pHa, without any alteration to PaCO2 (Table 1). The
magnitude of the changes in PaO2 and Sat Hb were similar
in all fetuses. In contrast, the decrement from baseline in
fetal pHa during acute hypoxia with saline vehicle infusion
(0.07  0.01) was enhanced during treatment with mela-
tonin high during NO blockade (0.09  0.01; P < 0.05;
Table 1). In addition, the maximal increment in fetal [Hb]
during acute hypoxia with saline vehicle infusion
(2.3  0.3 g/dL) was signiﬁcantly diminished during treat-
ment with melatonin low (1.0  0.1 g/dL), treatment with
melatonin high (0.7  0.2 g/dL), and treatment with mela-
tonin high during NO blockade (1.2  0.2 g/dL; Table 1).
During recovery, pHa remained signiﬁcantly depressed in
all fetuses, whereas PaO2, Sat Hb, and [Hb] returned
toward basal values (Table 1).
Basal values for fetal concentrations of blood glucose
and lactate were similar in all fetuses and were within the
normal range for the Welsh Mountain sheep fetus at ca.
130 days of gestation (Fig. 3). Infusion with saline vehicle,
treatment with melatonin low, treatment with melatonin
high, or treatment with melatonin high during NO
blockade had no eﬀect on basal metabolic status (Fig. 3).
Acute hypoxia during saline vehicle infusion induced
signiﬁcant increments from baseline in blood glucose
(0.85  0.35 mmol/L) and lactate (3.15  0.40 mmol/L)
concentrations. In contrast, treatment with melatonin low
(0.33  0.10 mmol/L) and treatment with melatonin high
(0.29  0.10 mmol/L) signiﬁcantly diminished the glycemic
response to acute hypoxia compared to saline vehicle-
infused controls. In addition, treatment with melatonin
high (2.07  0.21 mmol/L), but not treatment with melato-
nin low (2.72  0.23 mmol/L), signiﬁcantly attenuated the
lactic acidemic response to hypoxia. Treatment with mela-
tonin high during NO blockade recovered both the glyce-
mic and lactic acidemic responses toward control values as
seen with saline vehicle infusion (Fig. 3). During recovery,
blood glucose concentrations returned toward basal values,
while blood lactate concentrations remained signiﬁcantly
elevated in all fetuses (Fig. 3).
Basal values for fetal arterial blood pressure, heart rate,
FBF, and FVR were similar in all fetuses (Figs 4 and 5).
Infusion with saline vehicle, treatment with melatonin low,
treatment with melatonin high, and treatment with
melatonin high during NO blockade had no eﬀect on basal
cardiovascular function (Figs 4 and 5). Acute hypoxia
during saline vehicle infusion induced signiﬁcant incre-
ments from baseline in fetal arterial blood pressure
(10.0  1.8 mmHg) and FVR (5.27  0.99 mmHg
(mL/min)) and signiﬁcant falls in fetal heart rate (20  6
beats/min) and FBF (27  3 mL/min; Figs 4 and 5). In
contrast, treatment with melatonin low (5.4  0.7 mmHg)
Time periods
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Fig. 2. Fetal plasma concentrations of melatonin. Values represent
the mean  S.E.M. for plasma concentrations of melatonin at 0
(N0) and 75 (N75) min of normoxia, at 15 (H15) and 30 (H30) min
of hypoxia, and at 30 (R30) and 60 (R60) min of recovery for
fetuses exposed to 0.5-hr hypoxia (dashed box) during saline vehicle
infusion (○; n = 6), treatment with melatonin low (0.05  0.01 lg/
kg/min; ; n = 6), treatment with melatonin high (0.5  0.1 lg/kg/
min; ●; n = 6), or treatment with melatonin high during nitric
oxide (NO) blockade with the NO clamp (□; n = 6). Signiﬁcant dif-
ferences: aP < 0.05, versus time period N0; bP < 0.05, versus saline
vehicle infusion; cP < 0.05, melatonin low versus melatonin high
(two-way RMANOVA with post hoc Tukey test).
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and treatment with melatonin high (4.0  0.8 mmHg) sig-
niﬁcantly attenuated the magnitude of the mean pressor
response to acute hypoxia compared to saline vehicle-
infused controls. In addition, treatment with melatonin
low (FBF: 21  3 mL/min; FVR: 2.51  0.40 mmHg/
(mL/min)) and treatment with melatonin high (FBF:
16  2 mL/min; FVR: 0.99  0.18 mmHg/(mL/min))
signiﬁcantly attenuated the magnitude of the mean femo-
ral vasoconstrictor response to acute hypoxia in a
dose-dependent manner (Figs 4 and 5). Treatment with
melatonin high during NO blockade recovered the magni-
tude of both the mean pressor response (10.5 
1.6 mmHg) and the mean femoral vasoconstrictor
response (FBF: 27  3; FVR: 5.87  1.35 mmHg/(mL/
min)) toward control values as seen with saline vehicle
infusion (Figs 3 and 4). The bradycardic response to acute
hypoxia was not aﬀected by treatment with melatonin low
or treatment with melatonin high; however, the area under
the fetal heart rate curve was signiﬁcantly enhanced during
treatment with melatonin high during NO blockade com-
pared to saline vehicle-infused controls (Figs 4 and 5).
Treatment with melatonin low, treatment with melatonin
high, and treatment with melatonin high during NO
blockade also prevented the rebound tachycardia, which
was observed in saline vehicle-infused fetuses after the
hypoxic challenge (Figs 4 and 5). During recovery,
femoral blood ﬂow and vascular resistance returned
toward basal values by the end of the experimental proto-
col in all fetuses. In contrast, while fetal arterial blood
pressure and heart returned toward basal values in melato-
nin low- and melatonin high-treated fetuses, these vari-
ables remained signiﬁcantly altered from basal values in
melatonin high during NO blockade (Figs 4 and 5).
Basal values for fetal plasma concentrations of epineph-
rine and norepinephrine were similar in all fetuses (Fig. 6).
Infusion with saline vehicle, treatment with melatonin low,
treatment with melatonin high, and treatment with mela-
tonin high during NO blockade had no eﬀect on basal
Table 1. Fetal arterial blood gas and acid base status
Saline vehicle infusion or treatment with melatonin low or high (+/ NO clamp)
Normoxia Acute hypoxia Recovery
N0 N75 H5 H15 H30 R30 R60
pHa
Saline infusion 7.35  0.01 7.36  0.01 7.36  0.01 7.31  0.01a 7.28  0.01a 7.29  0.01a 7.32  0.01a
Melatonin (low) infusion 7.36  0.01 7.36  0.01 7.34  0.01 7.32  0.01a 7.29  0.01a 7.30  0.01a 7.33  0.01a
Melatonin (high) infusion 7.35  0.01 7.35  0.01 7.34  0.01 7.31  0.01a 7.30  0.01a 7.30  0.01a 7.32  0.01a
Melatonin (high) infusion
and NO clamp
7.34  0.01 7.34  0.01 7.33  0.01b 7.29  0.01a,b 7.25  0.01a,b 7.26  0.01a,b 7.28  0.01a,b
PaCO2 (mmHg)
Saline infusion 54.8  1.0 54.8  1.5 53.7  0.8 53.2  0.5 53.7  1.1 54.0  1.0 54.2  1.0
Melatonin (low) infusion 55.7  1.2 54.8  1.4 54.2  0.5 54.7  0.6 54.0  0.4 54.3  0.8 54.8  1.4
Melatonin (high) infusion 56.0  1.0 56.5  0.9 55.2  0.9 56.2  1.0 53.4  1.3 54.4  1.3 55.2  1.2
Melatonin (high) infusion
and NO clamp
56.2  0.9 55.3  1.0 54.0  0.9 54.8  0.7 54.7  0.7 54.3  1.0 54.8  1.0
PaO2 (mmHg)
Saline infusion 20.8  0.4 20.5  0.3 10.3  0.6a 10.7  0.6a 11.5  0.2a 21.0  0.6 20.7  0.2
Melatonin (low) infusion 20.5  0.6 20.8  0.5 10.8  0.4a 11.0  0.3a 11.7  0.2a 20.3  0.6 20.3  0.8
Melatonin (high) infusion 21.2  0.5 20.5  0.5 10.0  0.4a 11.2  0.3a 11.5  0.4a 20.0  0.5 20.2  0.5
Melatonin (high) infusion
and NO clamp
21.2  0.9 21.3  0.8 10.8  0.4a 11.8  0.3a 12.2  0.4a 21.0  0.9 21.3  0.8
Sat Hb (%)
Saline infusion 56.0  1.4 55.5  1.7 27.8  1.8a 25.7  1.5a 27.2  0.9a 54.8  2.1 53.9  0.9
Melatonin (low) infusion 54.6  2.2 55.2  2.1 27.2  1.3a 27.1  0.9a 27.6  1.2a 52.7  2.5 51.0  2.7
Melatonin (High) Infusion 53.2  1.8 52.1  1.9 25.7  0.7a 25.4  0.8a 26.3  1.4a 51.7  1.2 52.7  1.0
Melatonin (high) infusion
and NO clamp
56.7  3.1 56.4  3.3 25.6  1.7a 28.2  2.2a 29.4  2.1a 52.7  3.8 55.5  2.0
[Hb] (g/dL)
Saline infusion 9.2  0.1 9.3  0.1 11.2  0.3a 11.8  0.3a 11.4  0.5a 9.7  0.3 9.8  0.3
Melatonin (low) infusion 8.9  0.4 8.8  0.3 9.9  0.4a,b 9.9  0.4a,b 9.8  0.5a,b 8.8  0.6 8.9  0.6
Melatonin (high) infusion 9.2  0.5 9.1  0.6 9.7  0.6a,b 9.9  0.7a,b 9.7  0.7a,b 9.0  0.7 8.9  0.6
Melatonin (high) infusion
and NO clamp
8.7  0.4 8.7  0.4 9.4  0.4a,b 9.6  0.4a,b 9.9  0.5a,b 8.6  0.3 8.6  0.3
pHa, arterial pH; PaCO2, arterial partial pressure of CO2; PaO2, arterial partial pressure of O2; Sat Hb, percentage saturation of hemoglo-
bin with oxygen; [Hb], blood hemoglobin concentration.
Values represent the mean  S.E.M. at 0 (N0) and 75 (N75) min of normoxia, at 5 (H5), 15 (H15), and 30 (H30) min of hypoxia, and at
30 (R30) and 60 (R60) min of recovery for fetuses exposed to 0.5 hr of hypoxia during saline vehicle infusion (n = 6), treatment with mel-
atonin low (0.05  0.01 lg/kg/min; n = 6), treatment with melatonin high (0.5  0.1 lg/kg/min; n = 6), or treatment with melatonin
high during nitric oxide (NO) blockade with the NO clamp (n = 6).
Signiﬁcant diﬀerences: aP < 0.05, versus time period N0.
bP < 0.05, versus saline vehicle infusion (two-way RM ANOVA with post hoc Tukey test).
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catecholamine concentrations (Fig. 6). Acute hypoxia dur-
ing saline vehicle infusion induced signiﬁcant increments
in both concentrations of epinephrine (1243  392 pg/
mL) and norepinephrine (4576  1428 pg/mL; Fig. 6).
Treatment with melatonin low (epinephrine: 422  157
and norepinephrine: 1571  286 pg/mL) and treatment
with melatonin high (epinephrine: 77  60 and norepi-
nephrine: 1076  124 pg/mL) signiﬁcantly attenuated the
maximal increment in plasma catecholamines compared to
saline vehicle-infused controls (Fig. 6). The eﬀect on
plasma epinephrine concentrations was dose-dependent
(P < 0.05). In contrast, treatment with melatonin high
during NO recovered the plasma epinephrine response
(1156  470 pg/mL) to acute hypoxia back toward con-
trol values as seen with saline vehicle infusion. Although a
similar eﬀect was observed with the norepinephrine
response to acute hypoxia, the recovery was only partial
and, hence, the maximal increment (2591  764 pg/mL)
was still attenuated compared to saline vehicle-infused
controls (P < 0.05; Fig. 6). During recovery, plasma con-
centrations of epinephrine and norepinephrine returned
toward basal values in all fetuses (Fig. 6).
Discussion
The data from the present study show that melatonin
treatment diminishes the increase in fetal arterial blood
pressure, in FVR, in blood glucose, in blood lactate, and
in circulating plasma catecholamines during acute hypoxic
stress. These eﬀects of melatonin on stimulated cardiovas-
cular and metabolic functions in the fetus during acute
hypoxia were prevented by in vivo NO blockade. There-
fore, the data support the hypothesis that melatonin has a
signiﬁcant eﬀect on the fetal defense response to acute
hypoxia via increasing NO bioavailability. The use of mel-
atonin in pregnancy may weaken the capacity of the fetus
to respond to acute hypoxic stress.
A rapidly accumulating number of studies, including
our own, have reported that maternal treatment with mel-
atonin can be protective in early development complicated
by conditions of oxidative stress. Richter and colleagues
showed that melatonin improves placental eﬃciency and
birthweight and increases the placental expression of anti-
oxidant enzymes in undernourished pregnancy in rats [33].
The laboratory of Vohnnahme [10, 34] has reported that
maternal supplementation with melatonin in undernour-
ished pregnancy in sheep improves utero-placental blood
ﬂow. The melatonin-induced increase in placental and
umbilical arterial blood ﬂow is due to enhanced NO bio-
availability [9] and an increase in placental vessel sensitiv-
ity to bradykinin-induced relaxation [34]. However, in
other vascular beds, such as the coronary circulation, mel-
atonin has also been shown to inhibit NO-induced relaxa-
tion by acting on MT(2) receptors and PKG1 to increase
PDE5 phosphorylation, thereby decreasing cGMP accu-
mulation in response to NO [35]. Hence, the actions of
melatonin appear to change depending on the vascular
bed being studied.
Studies by the groups of Tare, Miller, and Herrera [11, 36,
37] have reported that maternal melatonin administration
mitigates cerebral oxidative stress, cerebrovascular and
endothelial dysfunction, and coronary stiﬀness in chroni-
cally hypoxic and growth-restricted lambs. Tain and col-
leagues [38] also reported in rats that melatonin therapy
prevents programmed hypertension and NO deﬁciency in
oﬀspring exposed to maternal caloric restriction. A collec-
tion of other studies has further reported that melatonin
and other antioxidants can protect against hypertension,
and cardiac and endothelial dysfunction induced by peri-
natal glucocorticoid therapy [39–42]. Understandably,
these long-term protective actions of melatonin have
prompted a clinical interest and expedited the design of
phase I clinical trials proposing that melatonin might miti-
gate morbidity and/or mortality in oﬀspring of pregnancy
complicated by oxidative stress in humans [13, 43]. How-
ever, these longer-term protective actions of melatonin in
oﬀspring of pregnancy aﬀected by sustained adverse intra-
uterine conditions have to be balanced against the possible
shorter-term adverse eﬀects of melatonin on the capacity
of the fetus to respond to acute hypoxic stress, such as
that associated with the imminent labor and delivery of
the fetus. This is because a series of studies in our labora-
tory has reported that an oxidant tone is functional in
peripheral resistance circulations of the fetus during late
gestation [9, 21–23]. Therefore, treatments with agents that
increase NO bioavailability might dampen the fetal periph-
eral vasoconstrictor response to acute hypoxia, which aids
the fetal brain sparing eﬀect.
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In this study, we show that treatment with melatonin
diminished the fetal in vivo peripheral vasoconstrictor
response to acute hypoxia in a dose-dependent manner and
that this eﬀect was reverted by in vivo NO blockade. There-
fore, the data show that the mechanism underlying the
depressive eﬀect of melatonin on fetal peripheral vasocon-
striction during acute hypoxia is via increasing NO
bioavailability. Interestingly, the doses of melatonin
administered to the fetus in the present experiments were
between 32 and 320 times lower than those recommended
to avoid jet lag in humans. Even at the higher dosing regi-
men (0.5  0.1 lg/kg/min), the total amount of melatonin
given to the fetus during the protocol was ca. 0.16 mg com-
pared to the 5.0 mg dose commonly taken to avoid jet lag
[30] or the 4.0 mg twice daily dose used in the current clini-
cal trial examining the antioxidant of melatonin in human
pregnancies complicated by fetal growth restriction [13].
Additional data in the present study show that treat-
ment of the fetus with melatonin diminished the fetal
plasma norepinephrine and epinephrine as well as the
fetal metabolic responses to acute hypoxia. Recent
studies have shown that melatonin acutely lowers norepi-
nephrine levels in the adult human [44] and gestational
melatonin deprivation in sheep results in increased
plasma norepinephrine in the newborn [45]; these eﬀects
of melatonin may be mediated in part via modulation of
central sympathetic outﬂow [46]. For instance, Wang
and colleagues [47] have reported that intracerebroven-
tricular administration of melatonin in pinealectomized
animals decreased sympathetic outﬂow, as measured by a
fall in plasma catecholamine concentrations. Central
eﬀects of melatonin on sympathetic outﬂow are sup-
ported by melatonin decreasing basal blood pressure
only in intact animals, but not in animals with spinal
transection [48]. Other studies have reported that melato-
nin treatment leads to a reduced activity of phenyletha-
nolamine-N-methyl transferase and monoamine oxidase,
adrenal medullary enzymes required for catecholamine
synthesis [49].
The fetal lactic academic response to acute hypoxia in
control fetuses arises from the anaerobic metabolism of
glucose in hypoxic fetal tissues, in particular the hind
limbs in which blood ﬂow is markedly reduced. Therefore,
the attenuated fetal plasma lactic acidemic response to
hypoxia in fetuses treated with melatonin is likely due to
the diminished fetal peripheral vasoconstrictor and hyper-
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glycemic responses to acute hypoxia [50]. The fetal hyper-
glycemia increases glucose availability to fetal tissues dur-
ing acute hypoxia and normally results from a decrease in
glucose uptake and utilization by peripheral tissues, cou-
pled with an increase in hepatic glucose production [51,
52]. As fetal treatment with the a-adrenergic antagonist,
phentolamine, prevented the glycemic response but
enhanced insulin secretion during hypoxia [51], both the
reduction in insulin-dependent glucose uptake and the
increase in glucose production by the fetal tissues may be
mediated via sympathetic a-adrenergic pathways under
these circumstances. Therefore, in the present study, sup-
pression of the fetal glycemic response to acute hypoxia
during fetal treatment with melatonin may represent an
eﬀect on insulin release and/or on the glucogenic pathways
mediated either by sympathetic ﬁbers and/or via elevations
in circulating catecholamines. Either way, a negative con-
tribution of melatonin to the activation of the sympathetic
adrenomedullary systems during acute hypoxic stress in
the late gestation sheep fetus is supported.
Following the end of melatonin treatment, a rapid fall
in plasma melatonin concentrations was noted in all
fetuses. This is not surprising considering that the half-
life of melatonin in fetal ovine plasma is ca. 25 min [53].
As melatonin can also cross the placenta [54–56], it may
also enter the maternal compartments where its half-life
has been reported to be as short as 2 min [53]; however,
maternal blood samples were not taken in the present set
of experiments. The primary site of melatonin metabo-
lism is the liver, where it is ﬁrst hydroxylated and then it
is excreted via the kidney as 6-hydroxymelatonin sulfate,
and to a lesser extent, as 6-hydroxymelatonin glucuronide
[57]. Due to the short half-life of melatonin, it is unlikely
that fetal treatment with melatonin on one experimental
day would aﬀect basal cardiovascular function on the
next experimental day. However, to ensure the lack of
possible eﬀects of pre-exposure to melatonin on basal
cardiovascular function, all experiments were conducted
in a randomized order in each of the animals, on consec-
utive days.
One ﬁnal consideration is how manipulation of the fetal
vascular oxidant tone by agents that increase NO bioavail-
ability, such as melatonin, may aﬀect vascular beds other
than the peripheral resistance circulations during acute
hypoxic stress. There is robust evidence that the cerebro-
vascular response to acute hypoxia involves active vasodi-
latation induced in part via NO-dependent mechanisms
[58]. In this context, pregnancies treated with melatonin
increasing NO bioavailability may on the one hand oppose
circulations that normally constrict during acute hypoxia,
such as the femoral vascular bed. On the other hand, mel-
atonin may actually maintain or enhance blood ﬂow in
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fetal circulations that normally dilate during acute
hypoxia, such as the cerebral vascular bed. Under condi-
tions of increased NO bioavailability induced by fetal
exposure to antioxidants, the fetal cardiovascular strategy
to withstand acute hypoxia may therefore switch to
increase cardiac output and maintain perfusion pressure,
in many ways, akin to the adult cardiovascular response
to acute hypoxia [59]. Studies that include parallel mea-
surement of peripheral and cerebral blood ﬂow in the
sheep fetus during acute hypoxia in the presence of antiox-
idant treatment in doses that are administered to humans
in healthy pregnancy as well as pregnancy complicated by
adverse intrauterine conditions are therefore essential to
establish the balance of potential beneﬁcial and adverse
eﬀects of fetal exposure to melatonin.
In summary, melatonin has direct eﬀects on the fetal
cardiovascular and metabolic defenses to acute hypoxia in
a dose-dependent manner via mechanisms involving
increased NO bioavailability and diminished plasma cate-
cholamine responses.
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